by | Jun 25, 2024 | Publications
Front Immunol. 2024 Jun 10;15:1405452. doi: 10.3389/fimmu.2024.1405452. eCollection 2024. ABSTRACT INTRODUCTION: Chimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment option for patients with relapsed or refractory multiple myeloma that has led...
by | Jun 25, 2024 | Publications
Sci Rep. 2024 Jun 24;14(1):14564. doi: 10.1038/s41598-024-65590-4. ABSTRACT Multiple myeloma (MM) is a plasma cell disorder accounting for approximately 10% of hematologic malignancies. There is limited epidemiological evidence regarding the long-term trends and...
by | Jun 25, 2024 | Publications
J Hematol Oncol. 2024 Jun 24;17(1):48. doi: 10.1186/s13045-024-01569-y. ABSTRACT It remains a substantial challenge to balance treatment efficacy and toxicity in geriatric patients with multiple myeloma (MM), primarily due to the dynamic nature of frailty. Here, we...
by | Jun 25, 2024 | Publications
Clin Nucl Med. 2024 Jun 21. doi: 10.1097/RLU.0000000000005351. Online ahead of print. ABSTRACT Brain nocardiosis is an uncommon but severe disease associated with high mortality. We present a case of brain nocardiosis with elevated tracer uptake on both...
by | Jun 24, 2024 | Publications
J Clin Oncol. 2024 Jun 24:JCO2400544. doi: 10.1200/JCO.24.00544. Online ahead of print. NO ABSTRACT PMID:38913961 | DOI:10.1200/JCO.24.00544
by | Jun 24, 2024 | Publications
Front Immunol. 2024 Jun 7;15:1393906. doi: 10.3389/fimmu.2024.1393906. eCollection 2024. ABSTRACT Infections are common in plasma cell cancer multiple myeloma (MM) due to disease-related immune deficiencies and cancer treatment. Myeloma cells express Toll-like...
